Developments BriaCell doses first patient in advanced breast cancer combination study BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF)initiated dosing in a Phase 1/2a clinical study of its lead product candidate, Bria-IMT, in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced... October 7, 2019